Chen Wei, Janz David R, Bastarache Julie A, May Addison K, O'Neal Hollis R, Bernard Gordon R, Ware Lorraine B
1Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN. 2Division of Pulmonary and Critical Care Medicine, Chia-Yi Christian Hospital, Taiwan, Republic of China. 3Department of Life Science, National Chung Hsing University, Taiwan, Republic of China. 4Department of Respiratory Therapy, China Medical University, Taiwan, Republic of China. 5Section of Pulmonary and Critical Care Medicine, Louisiana State University School of Medicine New Orleans, New Orleans, LA. 6Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN. 7Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN.
Crit Care Med. 2015 Apr;43(4):801-7. doi: 10.1097/CCM.0000000000000789.
Platelet activation plays an active role in the pathogenesis of acute respiratory distress syndrome. In our prior study of 575 patients at high risk for acute respiratory distress syndrome, concurrent statin and aspirin use was associated with reduced acute respiratory distress syndrome. However, the largest study (n = 3,855) to date found no significant benefit of prehospital aspirin in a lower-risk population when adjusted for the propensity for aspirin use. We aimed to determine whether prehospital aspirin use is associated with decreased acute respiratory distress syndrome in patients at high risk for acute respiratory distress syndrome after adjusting for the propensity to receive aspirin.
Secondary analysis of patients enrolled prospectively in the Validating Acute Lung Injury Markers for Diagnosis study.
A total of 1,149 critically ill patients (≥40 years old) admitted to the medical or surgical ICUs of an academic tertiary care hospital including 575 previously reported patients as well as additional patients who were enrolled after completion of the prior statin and aspirin study.
None.
Of 1,149 patients, 368 (32%) developed acute respiratory distress syndrome during the first 4 ICU days and 287 (25%) patients had prehospital aspirin use. Patients with prehospital aspirin had significantly lower prevalence of acute respiratory distress syndrome (27% vs 34%; p=0.034). In a multivariable, propensity-adjusted analysis including age, gender, race, sepsis, and Acute Physiology and Chronic Health Evaluation score II, prehospital aspirin use was associated with a decreased risk of acute respiratory distress syndrome (odds ratio, 0.66; 95% CI, 0.46-0.94) in the entire cohort and in a subgroup of 725 patients with sepsis (odds ratio, 0.60; 95% CI, 0.41-0.90).
In this selected cohort of critically ill patients, prehospital aspirin use was independently associated with a decreased risk of acute respiratory distress syndrome even after adjusting for the propensity of prehospital aspirin use. These findings support the need for prospective clinical trials to determine whether aspirin may be beneficial for the prevention of clinical acute respiratory distress syndrome.
血小板活化在急性呼吸窘迫综合征的发病机制中起积极作用。在我们之前对575例急性呼吸窘迫综合征高危患者的研究中,同时使用他汀类药物和阿司匹林与急性呼吸窘迫综合征的发生率降低相关。然而,迄今为止最大规模的研究(n = 3855)发现,在对阿司匹林使用倾向进行校正后,对于低风险人群,院前使用阿司匹林并无显著益处。我们旨在确定在对接受阿司匹林的倾向进行校正后,院前使用阿司匹林是否与急性呼吸窘迫综合征高危患者急性呼吸窘迫综合征发生率降低相关。
对前瞻性纳入“验证急性肺损伤诊断标志物”研究的患者进行二次分析。
共有1149例危重症患者(≥40岁)入住一家学术性三级医疗中心的内科或外科重症监护病房,其中包括之前报告的575例患者以及在先期他汀类药物和阿司匹林研究完成后纳入的其他患者。
无。
1149例患者中,368例(32%)在入住重症监护病房的前4天内发生急性呼吸窘迫综合征,287例(25%)患者院前使用过阿司匹林。院前使用阿司匹林的患者急性呼吸窘迫综合征的发生率显著较低(27%对34%;p = 0.034)。在一项多变量、倾向校正分析中,纳入年龄、性别、种族、脓毒症以及急性生理与慢性健康状况评分II,院前使用阿司匹林与整个队列以及725例脓毒症患者亚组中急性呼吸窘迫综合征风险降低相关(比值比,0.66;95%置信区间,0.46 - 0.94)(比值比,0.60;95%置信区间,0.41 - 0.90)。
在这个选定的危重症患者队列中,即使对院前使用阿司匹林的倾向进行校正后,院前使用阿司匹林仍与急性呼吸窘迫综合征风险降低独立相关。这些发现支持进行前瞻性临床试验以确定阿司匹林是否可能对预防临床急性呼吸窘迫综合征有益。